MikhailKosiborodMD

PubMed

• 15 citations
  SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.
  Vennela Avula, Garima Sharma, Mikhail N Kosiborod, Muthiah Vaduganathan, Tomas G Neilan
  JACC. Heart Failure. 2024-01-01
• 15 citations
  Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?
  Su E. Yeoh, Pooja Dewan, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber
  Circulation. Heart Failure. 2020-11-09
• 24 citations
  Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
  Pierpaolo Pellicori, David Fitchett, Mikhail Kosiborod, Anne Pernille Ofstad, Leo Seman
  European Journal of Heart Failure. 2021-06-28

Journal Articles

• Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction  
  Mikhail N Kosiborod, Marc S Sabatine, JAMA Cardiology
• Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and Without Diabetes  
  Akshay S Desai, Mikhail N Kosiborod, Marc S Sabatine, JAMA
• Real‐World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR® “Research‐to‐Practice” Project from the D...  
  Suzanne V Arnold, Mikhail Kosiborod, Diabetes, Obesity and Metabolism
• Management of Patients with Diabetes and Heart Failure with Reduced Ejection Fraction: An International Comparison  
  James L Januzzi, Mikhail Kosiborod, Frederick A Masoudi, Darren K McGuire, Suzanne V Arnold, Gregg C Fonarow, Diabetes, Obesity and Metabolism
• Join now to see all

Lectures

• Drug Choices in Diabetes and Heart Failure Advice for the Practicing Cardiologist 
  2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
• Changing Paradigm in Cardiovascular Risk Reduction in Diabetes 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• Initiation of Sodium Glucose Cotransporter-2 Inhibitors Versus Other Glucose Lowering Drugs and Risk of Hospitalization For Heart Failure and Death in Patients With Ty... 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• Summary of the ACC Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Diabetes 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• Comorbid Conditions in Heart Failure: Diabetes and All That Comes With it 
  2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
• Join now to see all